NewDays is building a new model of care for the millions of people living with mild cognitive impairment and early dementia, conditions where the traditional clinical response has too often been to wait and see. The company's program turns that into proactive treatment by combining telehealth appointments with licensed cognitive clinicians and frequent, guided cognitive exercises delivered between visits by an AI companion named Sunny. Built on decades of clinical research, the AI-led sessions provide specific evidence-based therapies, including cognitive stimulation, cognitive training, and cognitive rehabilitation.
The experience is designed to be accessible and structured. Patients begin with a free consultation, meet with cognitive specialists who oversee a personalized treatment plan, and then complete at-home, AI-guided brain exercises that Sunny adapts and coaches them through. By delivering therapy frequently and from home, NewDays makes it feasible to maintain the kind of consistent cognitive engagement that clinical evidence suggests can help slow decline.
NewDays points to peer-reviewed clinical data behind its approach, reporting that across several months of treatment a majority of patients showed improved cognitive function, many experienced improved mental health, and dementia patients delayed symptom progression by more than a year. The program is covered by Medicare and currently operates in California, Washington, and Florida, with plans to expand into additional states such as Texas.
The company was founded by Babak Parviz, a former leader at Amazon and Google X, together with Daniel Kelly, a former engineering leader at Amazon and Google X. In September 2025 NewDays announced $7 million in seed funding from General Catalyst and Madrona Venture Group to grow its team, expand to new states, and invest further in its AI platform. By combining licensed clinical oversight with a scalable generative-AI delivery layer, NewDays aims to make effective cognitive treatment widely available.
